Measles: Not just a childhood rash

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 3, 2010, Pages 207-213

  Sabella, Camille ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MEASLES VACCINE;

AGE DISTRIBUTION; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; ENCEPHALITIS; HUMAN; IMMUNOCOMPROMISED PATIENT; MEASLES; PNEUMONIA; REVIEW; RISK FACTOR; SUBACUTE SCLEROSING PANENCEPHALITIS; UNITED STATES;

AGE DISTRIBUTION; ENCEPHALITIS; HUMANS; IMMUNOCOMPROMISED HOST; MEASLES; MEASLES VACCINE; PNEUMONIA; RISK FACTORS; SUBACUTE SCLEROSING PANENCEPHALITIS; UNITED STATES; VACCINES, ATTENUATED;

EID: 77952821825     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.09123     Document Type: Review

References (40)

1. Lachmann PJ. Immunopathology of measles. Proc R Soc Med 1974; 67:1120-1122.
2. Enders JF, McCarthy K, Mitus A, Cheatham WJ. Isolation of measles virus at autopsy in case of giant cell pneumonia without rash. N Engl J Med 1959; 261:875-881.
3. Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 1990; 9:101-110.
4. Stokes J Jr, Reilly CM, Buynak EB, Hilleman MR. Immunologic studies of measles. Am J Hyg 1961; 74:293-303.
5. Farizo KM, Stehr-Green PA, Simpson DM, Markowitz LE. Pediatric emergency room visits: a risk factor for acquiring measles. Pediatrics 1991; 87:74-79.
6. Bloch AB, Orenstein W, Ewing WM, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75:676-683.
7. Remington PL, Hall WN, Davis IH, et al. Airborne transmission of measles in a physician's office. JAMA 1985; 253:1574-1577.
8. US Centers for Disease Control and Prevention. Reported vaccinepreventable diseases-United States, 1993, and the Childhood Immunization Initiative. MMWR 1994; 43:57-60.
9. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004; 189(suppl 1):S1-S3.
10. US Centers for Disease Control and Prevention. Update: Measles-United States, January-July 2008. MMWR 2008; 57:893-896.
11. Parker AA, Staggs W, Dayan GH, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006; 355:447-455.
12. Mulholland EK. Measles in the United States, 2006. N Engl J Med 2006; 355:440-443.
13. Barkin RM. Measles mortality. Analysis of the primary cause of death. Am J Dis Child 1975; 129:307-309.
14. Barkin RM. Measles mortality: a retrospective look at the vaccine era. Am J Epidemiol 1975; 102:341-349.
15. US Centers for Disease Control and Prevention. Public-sector vaccination efforts in response to the resurgence of measles among preschool-aged children-United States, 1989-1991. MMWR 1992; 41:522-525.
16. Gremillion DH, Crawford GE. Measles pneumonia in young adults. an analysis of 106 cases. Am J Med 1981; 71:539-542.
17. Quiambao BP, Gatchalian SR, Halonen P, et al. Coinfection is common in measles-associated pneumonia. Pediatr Infect Dis J 1998; 17:89-93.
18. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189(suppl 1):S4-S16.
19. Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis-clinical and immunologic studies. N Engl J Med 1984; 310:137-141.
20. Sever JL. Persistent measles infection of the central nervous system: subacute sclerosing panencephalitis. Rev Infect Dis 1983; 5:467-473.
21. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992; 14:217-226.
22. Gershon AA. Chickenpox, measles, and mumps. In: Remington J, Klein J, eds. Infectious Diseases of the Fetus and Newborn Infant. Elsevier Saunders: Philadelphia, 2006:693-738.
23. Mitus A, Enders JF, Craig JM, Holloway A. Persistence of measles virus and depression of antibody formation in patients with giant-cell pneumonia after measles. N Engl J Med 1959; 261:882-889.
24. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients JAMA 1992; 267:1237-1241.
25. Frey HM, Krugman S. Atypical measles syndrome: unusual hepatic, pulmonary, and immunologic aspects. Am J Med Sci 1981; 281: 51-55.
26. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202:1075-1080.
27. Mayo DR, Brennan T, Cormier DP, Hadler J, Lamb P. Evaluation of a commercial measles virus immunoglobulin M enzyme immunoassay. J Clin Microbiol 1991; 29:2865-2867.
28. Bellini WJ, Helfand RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. J Infect Dis 2003; 187(suppl 1):S283-S290.
29. Riddell MA, Chibo D, Kelly HA, Catton MG, Birch CJ. Investigation of optimal specimen type and sampling time for detection of measles virus RNA during a measles epidemic. J Clin Microbiol 2001; 39:375-376.
30. Forni Al, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994; 19:454-462.
31. Anders JF, Jacobsen RM, Poland GA, Jacobsen SJ, Wollan PC. Secondary failure rates of measles vaccines: a metaanalysis of published studes. Pediar Infect Dis J 1996; 15:62-66.
32. US Centers for Disease Control and Prevention. Measles-United States, January 1-April 25, 2008. MMWR 2008; 57:494-498.
33. Berkovitz S, Starr S. Use of live-measles-virus vaccine to abort an expected outbreak of measles within a closed population. N Engl J Med 1963; 269:75-77.
34. Ruuskanen O, Salmi TT, Halonen P. Measles vaccination after exposure to natural measles. J Pediatr 1978; 93:43-46.
35. Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Saunders: New York, 2004:389-440.
36. US Centers for Disease Control and Prevention. Measles, mumps and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998; 47(RR-8):1-57. http://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf. Accessed December 30, 2009.
37. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477-1482.
38. Straton K, Gable A, Shetty P, McCormick M, for the Institute of Medicine. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. National Academy Press: Washington, DC, 2001.
39. Pickerington LK, Baker CJ, Long SS, McMillan JA, editors. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009: 444-455.
40. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262-1266.